Post-Cycle Therapy (PCT): Planning Nolvadex, Clomid, and HCG Protocols

Post-cycle therapy (PCT) is the set of pharmacological tools used to restart the hypothalamic-pituitary-testicular axis (HPTA) after a period of exogenous androgen administration. Exogenous androgens suppress endogenous luteinizing hormone (LH) and follicle-stimulating hormone (FSH) via negative feedback, and the degree and duration of that suppression drives whether recovery is spontaneous, slow, or incomplete. The agents most commonly studied in this context — tamoxifen (Nolvadex), clomiphene citrate (Clomid), and human chorionic gonadotropin (HCG) — each act on a distinct node of the axis, which is why protocols typically combine rather than substitute them.

Why HPTA restoration matters

Suppression from supraphysiologic androgen exposure is well-characterized in the endocrinology literature. In studies of testosterone enanthate at 200–600 mg/week, serum LH and FSH fall to near-undetectable within two to four weeks, and intratesticular testosterone drops by roughly 90–95% within the same window. Leydig cell steroidogenic capacity and Sertoli cell function both decline secondarily. The clinical question PCT addresses is not whether suppression occurs — it reliably does — but how quickly and how completely the axis reboots once the suppressive signal is removed.

The published human data on recovery after androgen-induced suppression is mixed. The widely cited Rasmussen et al. 2016 contraceptive-withdrawal cohort found that a subset of former users showed persistent hypogonadism months to years after cessation, and a 2021 cross-sectional study in former anabolic-androgenic steroid (AAS) users reported a meaningful minority with testosterone below the reference range more than a year out. Researchers in the PCT literature generally frame the goal as compressing recovery time and reducing the tail risk of incomplete restoration, not as a guarantee.

Three endpoints matter: LH/FSH return, total and free testosterone recovery, and — where fertility is relevant — sperm concentration and motility. Sperm recovery is the slowest of the three and can lag hormonal normalization by several months, a point reported consistently in contraceptive-withdrawal studies dating back to the WHO male contraceptive trials.

Timing PCT start: half-life-based windows

PCT is ineffective — and potentially counterproductive — if initiated while meaningful exogenous androgen is still circulating. SERMs administered against a suppressed axis that is still receiving a strong negative-feedback signal cannot drive the upstream response they are designed to produce. The standard approach is to wait until serum androgen from the last ester has decayed into the low physiologic range, then begin.

The windows researchers commonly use are derived from ester half-lives reported in pharmacokinetic studies:

• Testosterone enanthate or cypionate: approximately 7–10 day terminal half-life. PCT start is typically two weeks after the last injection.
• Testosterone propionate: approximately 0.8–2 day half-life. PCT start is typically one week after the last injection.
• Trenbolone acetate: approximately 1 day half-life. PCT start is typically three days after the last injection.
• Nandrolone decanoate (Deca): approximately 6–12 day terminal half-life, with detectable metabolites persisting substantially longer. PCT start is typically four weeks after the last injection, and some researchers extend this.
• Oral 17α-alkylated compounds: half-lives of hours; PCT can begin within days of the last oral dose, though most protocols synchronize to the longest-acting injectable in the cycle.

When multiple compounds are run together, PCT start is governed by the compound with the longest half-life. A stack of testosterone cypionate and nandrolone decanoate would be timed off the nandrolone, not the testosterone.

SERMs: Nolvadex and Clomid

Selective estrogen receptor modulators (SERMs) act as competitive antagonists at the estrogen receptor in hypothalamic tissue. Estradiol is the primary negative-feedback signal at the hypothalamus — not testosterone directly — so blocking estrogen receptor activity at that site increases gonadotropin-releasing hormone (GnRH) pulse amplitude and frequency, which in turn raises pituitary LH and FSH output.

Nolvadex (tamoxifen citrate)

Tamoxifen is the more tissue-selective of the two common SERMs in PCT use. In the published PCT-adjacent literature, doses of 20–40 mg per day have been used, typically 20 mg daily for milder suppression scenarios and 40 mg for the first one to two weeks of a longer protocol before tapering. A 2003 study by Tsourdi et al. and several earlier trials in idiopathic oligospermia reported measurable rises in LH, FSH, and total testosterone on 20 mg daily tamoxifen within four to six weeks. Side effect profile in these studies was generally mild, with visual disturbances and mood changes reported at low frequency.

Clomid (clomiphene citrate)

Clomiphene is a mixture of two isomers (enclomiphene and zuclomiphene) with different pharmacokinetics; zuclomiphene has a much longer half-life and accumulates with repeated dosing. This accumulation is one reason clomiphene is associated with more reported visual and mood side effects than tamoxifen at equipotent doses. Typical PCT doses are 50–100 mg per day, often 100 mg for the first week or two then 50 mg through the remainder. Katz et al. 2012 and subsequent hypogonadism cohorts have reported LH, FSH, and testosterone responses comparable to tamoxifen at the dose ranges listed above.

Combination SERM protocols

Running Nolvadex and Clomid together is common in the applied PCT literature because the two have overlapping but not identical tissue selectivity, and because the combination allows slightly lower doses of each. A representative four-week protocol reported in practitioner-facing reviews is:

• Weeks 1–2: Clomid 50 mg/day + Nolvadex 20 mg/day
• Weeks 3–4: Clomid 25 mg/day + Nolvadex 10 mg/day

Longer protocols (five to six weeks) are used after deeper or longer suppressive cycles. The question of whether combination outperforms monotherapy on hard endpoints (testosterone recovery time, sperm parameters) has not been cleanly resolved in published controlled trials; most evidence is observational.

HCG: the pre-PCT bridge

HCG is a placental glycoprotein that binds the LH receptor on Leydig cells and directly stimulates intratesticular testosterone and steroidogenesis. Unlike SERMs, it does not act upstream at the hypothalamus or pituitary — it bypasses them. Its role in a PCT plan is therefore different: it maintains testicular size and steroidogenic capacity during suppression, and it addresses the atrophy and Leydig cell desensitization that accumulate on long cycles.

The typical bridge protocol is 250–500 IU every other day (EOD) during the final two weeks before SERM PCT begins. A 2005 study by Coviello et al. reported that 250 IU EOD was sufficient to maintain intratesticular testosterone in men on exogenous testosterone, and 500 IU EOD was used in subsequent protocols as a more conservative maintenance dose. HCG is generally stopped before SERMs are introduced, because running HCG concurrently with SERMs suppresses LH via the now-restored negative feedback loop, partly defeating the purpose of the SERM.

HCG used at high doses or for extended periods carries its own suppression and desensitization concerns. Prolonged high-dose HCG can itself downregulate the Leydig cell LH receptor, and it can elevate estradiol via increased intratesticular aromatization. These are the reasons the bridge is kept short and moderate in dose.

Putting the protocol together

A synthesized PCT plan, drawing from the windows above, for a hypothetical testosterone enanthate cycle might look as follows. This is illustrative, not prescriptive.

• Final two weeks of cycle: HCG 500 IU EOD, continuing testosterone enanthate to scheduled cycle end.
• Stop HCG at cycle end. Stop testosterone at cycle end.
• Wait 14 days (two half-lives of testosterone enanthate sufficient for serum androgen to fall into low-normal range).
• Weeks 1–2 of PCT: Nolvadex 40 mg/day + Clomid 50 mg/day.
• Weeks 3–4 of PCT: Nolvadex 20 mg/day + Clomid 25 mg/day.
• Optional week 5–6 taper for longer or heavier cycles.

For a nandrolone-containing cycle, the 14-day wait extends to approximately four weeks, and the SERM duration is typically lengthened. For a short trenbolone acetate cycle, the wait compresses to three days but the SERM duration stays the same, as PCT duration is governed by how suppressed the axis was, not by how fast the ester cleared.

Bloodwork milestones

Useful serial measurements in the published literature include:

• Baseline (pre-cycle): total testosterone, free testosterone, LH, FSH, estradiol (sensitive assay), SHBG, prolactin, and — if fertility matters — a semen analysis.
• Mid-PCT (around week 2–3): LH and FSH to confirm the SERM is producing a gonadotropin response.
• Two to four weeks post-PCT: total testosterone, free testosterone, LH, FSH, estradiol.
• Eight to twelve weeks post-PCT: repeat panel. Sperm parameters, if relevant, are re-assessed at three and six months, since spermatogenesis recovers on a slower timescale than hormonal recovery.

Researchers use these checkpoints to detect incomplete recovery early. A flat LH response at week three of PCT, or testosterone still in the low hypogonadal range two months out, is the signal that the axis has not restarted on the initial protocol and that extended intervention may be warranted.

Open questions

Several areas in the PCT literature remain unresolved. The comparative efficacy of tamoxifen monotherapy versus combination SERM therapy on time-to-recovery has not been tested in adequately powered controlled trials. The optimal HCG bridge dose and duration — and whether a bridge adds measurable benefit over SERM-only PCT in shorter cycles — is similarly underdetermined. Enclomiphene citrate as a monotherapy alternative to racemic clomiphene has generated recent interest, with Wiehle et al. and subsequent trials reporting favorable LH and testosterone responses with a cleaner side-effect profile, but its place in post-cycle protocols specifically has not been well-studied. Finally, the long-tail question — why a subset of former users show persistent hypogonadism despite completed PCT — remains open, and likely reflects a combination of cycle length, compound choice, individual HPTA resilience, and age at first use. Researchers designing protocols should treat the published dose ranges as starting points and rely on serial bloodwork, not fixed templates, to characterize response.